Administration of Fingolimod in Greek Patients With Multiple Sclerosis.

Launched by ELPEN PHARMACEUTICAL CO. INC. · Apr 28, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the effectiveness of a medication called fingolimod in people with relapsing-remitting multiple sclerosis (RRMS). The study aims to see how well fingolimod works by measuring the number of relapses (or flare-ups) patients experience over two years. Participants will be individuals who are already taking fingolimod as part of their treatment and will be asked to provide information about their health history from the past year and ongoing health for the next two years.

To be eligible for this study, participants must be at least 18 years old, have a confirmed diagnosis of RRMS, and have been on fingolimod for at least a year. They should also be able to follow the study's requirements and not have any conditions that would prevent them from participating. The trial is still in the planning stages and has not started recruiting participants yet. If you're considering joining, you'll have the chance to share your experiences with fingolimod and contribute to important research in MS treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients over 18 years of age.
• • 2. Consent and compliance of participants with the treatments and procedures of the study.
• • 3. Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) according to the revised McDonald 2017 criteria.
• • 4. Patients who are receiving fingolimod, according to the drug's Summary of product Characteristics (SmPC).
• • 5. Patients with available follow-up data for at least 12 months prior to their inclusion in the study, which are sufficient to calculate the annualized relapse rate.
• Exclusion Criteria:
• • 1. Patients under 18 years of age.
• • 2. Patients with a contraindication to taking fingolimod according to the drug's Summary of product Characteristics (SmPC).
• • 3. Patients with a history of mental illness, substance abuse, to a degree that may prevent their participation in the study.
• • 4. Patients participating in another research protocol.